Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Neuberg Diagnostics unveils Neubee to make preventive healthcare simpler

New digital health companion uses friendly, jargon-free communication to help users better understand reports

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial

Merck emphasized the broader significance of the findings

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

FDA nod to AstraZeneca’s Imfinzi plus FLOT chemotherapy for early and locally advanced gastric cancer

Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day

Cosmo and Glenmark receives market authorization of Winlevi in Europe

Winlevi is authorized in EU for the treatment of acne vulgaris

FDA nod to Koselugo for adults with Rare NF1 tumors, expanding life-changing treatment